Vorinostat in solid and hematologic malignancies

Abstract

Vorinostat (Zolinza ® ), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. This review summarizes evidence on the use of vorinostat in solid and hematologic malignancies and collated tolerability data from the vorinostat clinical trial program. Pooled vorinostat clinical trial data from 498 patients with solid or hematologic malignancies show that vorinostat was well tolerated as monotherapy or combination therapy. The most commonly reported drug-related adverse events (AEs) associated with monotherapy (n = 341) were fatigue (61.9%), nausea (55.7%), diarrhea (49.3%), anorexia (48.1%), and vomiting (32.8%), and Grade 3/4 drug-related AEs included fatigue (12.0%), thrombocytopenia (10.6%), dehydration (7.3%), and decreased platelet count (5.3%). The most common drug-related AEs observed with vorinostat in combination therapy (n = 157, most of whom received vorinostat 400 mg qd for 14 days) were nausea (48.4%), diarrhea (40.8%), fatigue (34.4%), vomiting (31.2%), and anorexia (20.4%), with the majority of AEs being Grade 2 or less. In Phase I trials, combinations with vorinostat were generally well tolerated and preliminary evidence of anticancer activity as monotherapy or in combination with other systemic therapies has been observed across a range of malignancies. Ongoing and planned studies will further evaluate the potential of vorinostat in combination therapy, including combinations with radiation, in patients with diverse malignancy types, including non-small-cell lung cancer, glioblastoma multiforme, multiple myeloma, and myelodysplastic syndrome. Histone Deacetylase Inhibition with Vorinostat as a Target in OncologyAdvanced or refractory malignancy remains an area of high unmet medical need as patients often relapse and curative therapy is elusive. The mainstay of treatment is generally cytotoxic chemotherapy which can have limited efficacy and is often associated with significant toxicity; there is a need for novel agents that are not only effective

Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming

“…HDAC inhibitors have been used in combination with ATRA to treat certain types of leukemia 21,25 and with corticoids in multiple myeloma and peripheral T-cell lymphoma patients. 48,49 Studies combining retinoids and HDAC inhibitors in a xenograft model of neuroblastoma revealed synergistic effects and increased survival.…”

“…These include histone deacetylase (HDAC) inhibitors, in hematological malignancies and cutaneous T-cell lymphomas, and inhibitors of DNA methylation such as azacytidine for myelodysplasic syndrome. 25 These drugs have been tested in non-small cell lung cancer (NSCLC) patients in two studies, in which they showed no major responses. 26,27 However, in a phase I/II trial, the combination of the two inhibitors produced a median survival of the entire cohort that was significantly longer than those of the existing therapeutic options.…”

Tempol prevents genotoxicity induced by vorinostat: role of oxidative DNA damage

“…It has been approved in the United States for the treatment of patients with relapsed and refractory cutaneous T cell lymphoma that has progressive, persistent or recurrent disease on or following two systemic therapies (Prebet and Vey 2011;Mann et al 2007;Siegel et al 2009). …”

Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells

“…These result in the re-expression of silenced genes involved in cell cycle arrest (6), DNA repair (7) and apoptosis pathways (8). Such effects are translated into antitumor activities in a variety of cancer types (9), thereby highlighting the potential of HDACIs for widespread utility.…”